Larvol Delta - Agios-Pharmaceuticals-Incannounced-that-it-will-not-advance-tebapivat-a-nextgeneration-oral-pyruvate-kinase-PK-activator-in-lowerrisk-myelodysplastic-syndromes-LRMDS

tebapivat (AG-946) - Agios Pharmaceuticals

https://www.globenewswire.com/news-release/2026/05/29/3303496/31990/en/Agios-Provides-Update-on-Phase-2b-Trial-of-Tebapivat-in-Lower-Risk-Myelodysplastic-Syndromes.html

May 29, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next